Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
IMV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
7 hours ago
businesswire.com
12 hours ago
businesswire.com
16 hours ago
prnewswire.com
16 hours ago
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Pre-market 0.73$
-0.09 (-11.15%)
Relative Strenght
0
Volume Buzz
-71%
Earning Acce
Yes
Dist 52w H.
79%Relative Strength
IMV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q3.20
N/A
-1.00
vsĀ -1.20
Q4.20
N/A
-1.10
vsĀ -1.30
Q1.21
N/A
-1.00
vsĀ -1.40
Q2.21
N/A
-1.10
vsĀ -0.90
Q3.21
N/A
-1.30
vsĀ -1.00
Q4.21
N/A
-1.40
vsĀ -1.10
Q1.22
N/A
-1.30
vsĀ -1.00
Q2.22
N/A
-1.20
vsĀ -1.10
Q3.22
N/A
-1.10
vsĀ -1.30
Q4.22
N/A
-0.99
vsĀ -1.40
Sales Growth
YoY
Current
Estimates
Q3.20
-77%
2.2KĀ vsĀ 9.8K
Q4.20
-100%
111.431503Ā vsĀ 25.5K
Q1.21
NA
NAĀ vsĀ NA
Q2.21
NA
NAĀ vsĀ NA
Q3.21
-100%
NAĀ vsĀ 2.2K
Q4.21
-100%
NAĀ vsĀ 111.431503
Q1.22
NA
NAĀ vsĀ NA
Q2.22
NA
NAĀ vsĀ NA
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q3.20
NA
NA
vsĀ NA
Q4.20
NA
NA
vsĀ NA
Q1.21
NA
NA
vsĀ NA
Q2.21
NA
NA
vsĀ NA
Q3.21
NA
NA
vsĀ NA
Q4.21
-54%
-0.54
vsĀ -0.32
Q1.22
-91%
-0.91
vsĀ -0.54
Q2.22
-406%
-4.06
vsĀ -0.91
Q3.22
+134%
1.34
vsĀ -4.06
Q4.22
+131%
1.31
vsĀ 1.34
Institutionnal Ownership
QoQ
Q2.20
26
26
vsĀ 23
13%
Q3.20
39
39
vsĀ 26
50%
Q4.20
42
42
vsĀ 39
8%
Q1.21
35
35
vsĀ 42
-17%
Q2.21
35
35
vsĀ 35
NA
Q3.21
32
32
vsĀ 35
-9%
Q4.21
38
38
vsĀ 32
19%
Q1.22
36
36
vsĀ 38
-5%
Q2.22
37
37
vsĀ 36
3%
Q3.22
33
33
vsĀ 37
-11%